Lawyers for Genentech Inc. and the University of California wrapped up their arguments Thursday in a fiercely contested patent battle over one of the most lucrative biotech inventions of the century.
Jurors in San Francisco federal court will begin deliberating Monday to determine which of the two institutions has the superior patent to human growth hormone, a wonder drug of sorts that has widespread medical applications, including combatting old age and helping children with growth problems.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
